Pharmacokinetic parameter prediction from drug structure using artificial neural networks.
暂无分享,去创建一个
[1] P. Hinderling,et al. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man , 1984, Journal of Pharmacokinetics and Biopharmaceutics.
[2] H. Black,et al. A comprehensive review of the clinical pharmacology and pharmacokinetics of cefaclor. , 1988, Clinical Therapeutics.
[3] T. Ghafourian,et al. The effect of structural QSAR parameters on skin penetration. , 2001, International journal of pharmaceutics.
[4] T. Bergan. Comparative pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration. , 1977, Chemotherapy.
[5] Romankiewicz Ja,et al. Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections. , 1983 .
[6] Rf Rekker,et al. THE HYDROPHOBIC FRAGMENTAL CONSTANT; AN EXTENSION TO A 1000 DATA POINT SET , 1979 .
[7] K Krishnan,et al. Quantitative structure-pharmacokinetic relationship modelling. , 2001, The Science of the total environment.
[8] J Bourquin,et al. Basic concepts of artificial neural networks (ANN) modeling in the application to pharmaceutical development. , 1997, Pharmaceutical development and technology.
[9] M. Ehrnebo,et al. Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man , 1979, Journal of Pharmacokinetics and Biopharmaceutics.
[10] P. Veng‐Pedersen,et al. Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series. , 1994, Journal of pharmaceutical sciences.
[11] M. Schulz,et al. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment , 2004, European Journal of Clinical Pharmacology.
[12] J. Quion,et al. Clinical Pharmacokinetics of Pravastatin , 1994, Clinical pharmacokinetics.
[13] A Ward,et al. Pentoxifylline , 1987, Drugs.
[14] D. Nicolau,et al. Lomefloxacin Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.
[15] D. Maddalena,et al. Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks. , 1995, Journal of medicinal chemistry.
[16] U. Gundert-Remy,et al. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment , 2004, European Journal of Clinical Pharmacology.
[17] L. Benet,et al. Pharmacokinetics of natural and synthetic glucocorticoids , 1985 .
[18] M. Feher,et al. A simple model for the prediction of blood-brain partitioning. , 2000, International journal of pharmaceutics.
[19] B. Huitfeldt,et al. Intra- and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers. , 1986, British journal of clinical pharmacology.
[20] D. Breimer,et al. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. , 1991, British journal of clinical pharmacology.
[21] G. Drusano,et al. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate , 1989, Antimicrobial Agents and Chemotherapy.
[22] S. Schenker,et al. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction. , 1977, Gastroenterology.
[23] P. Benfield,et al. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. , 1990, Drugs.
[24] Didier Villemin,et al. Neural networks studies : quantitative structure-activity relationship of mutagenic aromatic nitro compounds , 1993 .
[25] W. Shelver,et al. Quantitative structure-pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks. , 1995, Journal of pharmaceutical sciences.
[26] Snezana Agatonovic-Kustrin,et al. Multiple pharmacokinetic parameter prediction for a series of cephalosporins. , 2003, Journal of pharmaceutical sciences.
[27] T. Schwinghammer,et al. Pharmacokinetics of Cephradine Administered Intravenously and Orally to Young and Elderly Subjects , 1990, Journal of clinical pharmacology.
[28] P. Meredith,et al. Clinical Pharmacokinetics of Amlodipine , 1992, Clinical Pharmacokinetics.
[29] R. Moore,et al. Pharmacokinetics of betamethasone in healthy adults after intravenous administration , 2004, European Journal of Clinical Pharmacology.
[30] Ian Spence,et al. Selective descriptor pruning for QSAR/QSPR studies using artificial neural networks , 2003, J. Comput. Chem..
[31] Jerome J. Schentag,et al. Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients , 1981, Clinical pharmacology and therapeutics.
[32] U. Stephan,et al. Pharmacokinetic Disposition of Quinolones in Human Body Fluids and Tissues , 1989, Clinical pharmacokinetics.
[33] W. Colburn,et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain , 1987, Clinical pharmacology and therapeutics.
[34] Facundo Pérez-Giménez,et al. QSAR Analysis of Hypoglycemic Agents Using the Topological Indices , 2001, J. Chem. Inf. Comput. Sci..
[35] D. Greenblatt,et al. Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration , 1986, Journal of clinical pharmacology.
[36] J. Upward,et al. Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects , 2004, European Journal of Clinical Pharmacology.
[37] S. Ōmura,et al. Inhibition of Sporulation by Cerulenin and Its Reversion by Exogenous Fatty Acids in Saccharomyces cerevisiae , 1976, Antimicrobial Agents and Chemotherapy.
[38] M. Eichelbaum,et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose‐dependent clearance, and interaction with amiodarone , 1994, Clinical pharmacology and therapeutics.
[39] P. Sebel,et al. The Pharmacokinetics of Sufentanil in Surgical Patients , 1984, Anesthesiology.
[40] J. Hamilton-miller,et al. Cefaclor into the millennium. , 1999, Journal of chemotherapy.
[41] P J Sinko,et al. Development of predictive pharmacokinetic simulation models for drug discovery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[42] F. Sallee,et al. Clinical Pharmacokinetics of Imipramine and Desipramine , 1990, Clinical pharmacokinetics.
[43] P. Kroboth,et al. Pharmacokinetics of the Newer Benzodiazepines , 1989, Clinical pharmacokinetics.
[44] G. Houin,et al. Clinical Pharmacokinetics of Doxycycline and Minocycline , 1988, Clinical pharmacokinetics.
[45] K. Hamunen,et al. Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children , 1995, Clinical pharmacokinetics.
[46] Arup K. Ghose,et al. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..
[47] E. Sellers,et al. Clinical Pharmacokinetics of Non-Opiate Abused Drugs , 1989, Clinical pharmacokinetics.
[48] P. Welling,et al. Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. , 1982, Biopharmaceutics & drug disposition.
[49] A. Favero,et al. Ondansetron Clinical Pharmacokinetics , 1995, Clinical pharmacokinetics.
[50] Subhash C. Basak,et al. Topological Indices: Their Nature and Mutual Relatedness , 2000, J. Chem. Inf. Comput. Sci..
[51] K. Lauritsen,et al. Clinical pharmacolinetics of drugs used in the treatment of gastrointestinal diseases. I , 1990 .
[52] G. Grass,et al. Effect of diverse datasets on the predictive capability of ADME models in drug discovery , 2001 .
[53] Y L Loukas,et al. Quantitative structure-binding relationships (QSBR) and artificial neural networks: improved predictions in drug:cyclodextrin inclusion complexes. , 2001, International journal of pharmaceutics.
[54] E. Bailey,et al. Ofloxacin Clinical Pharmacokinetics , 1992, Clinical pharmacokinetics.
[55] S. Agatonovic-Kustrin,et al. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. , 2000, Journal of pharmaceutical and biomedical analysis.
[56] W. Jusko,et al. Gender‐based effects on methylprednisolone pharmacokinetics and pharmacodynamics , 1993, Clinical pharmacology and therapeutics.
[57] S. So,et al. Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors. , 1992, Journal of medicinal chemistry.
[58] D. Orth.,et al. THE ADRENAL CORTEX , 1948 .
[59] K J Schaper,et al. Quantitative structure-pharmacokinetic relationships and drug design. , 1981, Pharmacology & therapeutics.
[60] F. Jamali,et al. Clinical Pharmacokinetics of Ketoprofen and Its Enantiomers , 1990, Clinical pharmacokinetics.
[61] D. Greenblatt. Clinical Pharmacokinetics of Oxazepam and Lorazepam , 1981, Clinical pharmacokinetics.
[62] J N Weinstein,et al. Neural computing in cancer drug development: predicting mechanism of action. , 1992, Science.
[63] T. A. Andrea,et al. Applications of neural networks in quantitative structure-activity relationships of dihydrofolate reductase inhibitors. , 1991, Journal of medicinal chemistry.
[64] R. Oberbauer,et al. Pharmacokinetics of Indomethacin in the Elderly , 1993, Clinical pharmacokinetics.
[65] C J Timmer,et al. Clinical Pharmacokinetics of Mirtazapine , 2000, Clinical pharmacokinetics.
[66] J. Rask-Madsen,et al. Clinical Pharmacokinetics of Drugs Used in the Treatment of Gastrointestinal Diseases (Part I) , 1990, Clinical pharmacokinetics.
[67] J. Flaherty,et al. Third-generation cephalosporins: a critical evaluation. , 1984, Clinical pharmacy.
[68] J P Monk,et al. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. , 1987, Drugs.
[69] Jesús Vicente de Julián-Ortiz,et al. Topological Approach to Drug Design , 1995, J. Chem. Inf. Comput. Sci..
[70] P. Dick,et al. Discrepancies Between Pharmacokinetic Studies of Amitriptyline , 1985, Clinical pharmacokinetics.
[71] T. Hatanaka. Clinical Pharmacokinetics of Pravastatin , 2000, Clinical pharmacokinetics.
[72] Ramón García-Domenech,et al. Topological Approach to Analgesia , 1994, J. Chem. Inf. Comput. Sci..
[73] A. Burm,et al. Clinical Pharmacokinetics of Epidural and Spinal Anaesthesia , 1989, Clinical pharmacokinetics.
[74] M. Eichelbaum,et al. Clinical Pharmacokinetics of Verapamil, Nifedipine and Diltiazem , 1986, Clinical pharmacokinetics.
[75] D. Spyker,et al. Pharmacokinetics of Cefaclor and Cephalexin: Dosage Nomograms for Impaired Renal Function , 1978, Antimicrobial Agents and Chemotherapy.
[76] A. Munafo,et al. Disposition and irreversible plasma protein binding of tolmetin in humans , 1988, Clinical pharmacology and therapeutics.
[77] L. Hall,et al. Molecular Structure Description: The Electrotopological State , 1999 .
[78] S. Unger. Molecular Connectivity in Structure–activity Analysis , 1987 .